Publications

Interim Report 2022

HAEMATO AG was able to continue its profitable growth course in the „Specialty Pharma“ and „Lifestyle & Aesthetics“ segments in the first half of 2022. This was achieved despite the fact that the special effects from the COVID-19 Diagnostics business unit, which made an extraordinarily positive contribution to earnings in the previous year, have largely disappeared.

• Download report